Tier 2 — strong

Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo

Inka Boomgaarden, Sarah Egert, Gerald Rimbach, Siegfried Wolffram, Manfred J Müller, Frank Döring
The British journal of nutrition 2010 104(3):336

Bibliography

PubMed
PMID 20416132
DOI
10.1017/S0007114510000711
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman gene-expression discovery study with placebo-controlled crossover verification
ModelHuman intervention research
Sample20 participants in the verification cohort; discovery sample not specified in the abstract
InterventionQuercetin 150 mg/day in the verification study
Duration2-week discovery intervention; 6-week crossover periods in verification
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2010, this source examined evidence reviews and human mechanisms. Design: Human gene-expression discovery study with placebo-controlled crossover verification. Sample/model: 20 participants in the verification cohort; discovery sample not specified in the abstract. The exposure or intervention was Quercetin 150 mg/day in the verification study. Follow-up or treatment period: 2-week discovery intervention; 6-week crossover periods in verification.

Initial microarray signals were poorly replicated; only small changes in a few targets distinguished quercetin from placebo.

Exploratory transcriptomics with weak independent confirmation. Gene-expression signals do not establish clinical benefit or a reliably activated longevity pathway.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Initial microarray signals were poorly replicated; only small changes in a few targets distinguished quercetin from placebo.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 150 mg/day in the verification study; 2-week discovery intervention; 6-week crossover periods in verification.

What this study can and cannot tell us

  • Exploratory transcriptomics with weak independent confirmation. Gene-expression signals do not establish clinical benefit or a reliably activated longevity pathway.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study
Sarah Egert et al. · The British journal of nutrition · 2009
Tier 2
Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype
Sarah Egert et al. · The Journal of nutrition · 2010
Tier 2
Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes--role of quercetin metabolism
Christine Boesch-Saadatmandi et al. · International journal of molecular sciences · 2009

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology